|
US3180193A
(en)
|
1963-02-25 |
1965-04-27 |
Benedict David |
Machines for cutting lengths of strip material
|
|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4179337A
(en)
|
1973-07-20 |
1979-12-18 |
Davis Frank F |
Non-immunogenic polypeptides
|
|
JPS5612114B2
(pl)
|
1974-06-07 |
1981-03-18 |
|
|
|
US4263428A
(en)
|
1978-03-24 |
1981-04-21 |
The Regents Of The University Of California |
Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
|
|
US4231938A
(en)
|
1979-06-15 |
1980-11-04 |
Merck & Co., Inc. |
Hypocholesteremic fermentation products and process of preparation
|
|
JPS6023084B2
(ja)
|
1979-07-11 |
1985-06-05 |
味の素株式会社 |
代用血液
|
|
AU548996B2
(en)
|
1980-02-04 |
1986-01-09 |
Merck & Co., Inc. |
Tetrahydro-2h-pyran-2-one derivatives
|
|
US4444784A
(en)
|
1980-08-05 |
1984-04-24 |
Merck & Co., Inc. |
Antihypercholesterolemic compounds
|
|
US4399216A
(en)
|
1980-02-25 |
1983-08-16 |
The Trustees Of Columbia University |
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
|
|
IE52535B1
(en)
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
|
US4640835A
(en)
|
1981-10-30 |
1987-02-03 |
Nippon Chemiphar Company, Ltd. |
Plasminogen activator derivatives
|
|
DE3374837D1
(en)
|
1982-02-17 |
1988-01-21 |
Ciba Geigy Ag |
Lipids in the aqueous phase
|
|
HUT35524A
(en)
|
1983-08-02 |
1985-07-29 |
Hoechst Ag |
Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
|
|
DE3474511D1
(en)
|
1983-11-01 |
1988-11-17 |
Terumo Corp |
Pharmaceutical composition containing urokinase
|
|
US4496689A
(en)
|
1983-12-27 |
1985-01-29 |
Miles Laboratories, Inc. |
Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
|
|
US4740461A
(en)
|
1983-12-27 |
1988-04-26 |
Genetics Institute, Inc. |
Vectors and methods for transformation of eucaryotic cells
|
|
EP0206448B1
(en)
|
1985-06-19 |
1990-11-14 |
Ajinomoto Co., Inc. |
Hemoglobin combined with a poly(alkylene oxide)
|
|
US4791192A
(en)
|
1986-06-26 |
1988-12-13 |
Takeda Chemical Industries, Ltd. |
Chemically modified protein with polyethyleneglycol
|
|
US4959455A
(en)
|
1986-07-14 |
1990-09-25 |
Genetics Institute, Inc. |
Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
|
|
US5260203A
(en)
|
1986-09-02 |
1993-11-09 |
Enzon, Inc. |
Single polypeptide chain binding molecules
|
|
EP0281604B1
(en)
|
1986-09-02 |
1993-03-31 |
Enzon Labs Inc. |
Single polypeptide chain binding molecules
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US4912040A
(en)
|
1986-11-14 |
1990-03-27 |
Genetics Institute, Inc. |
Eucaryotic expression system
|
|
GB8823869D0
(en)
|
1988-10-12 |
1988-11-16 |
Medical Res Council |
Production of antibodies
|
|
US5175384A
(en)
|
1988-12-05 |
1992-12-29 |
Genpharm International |
Transgenic mice depleted in mature t-cells and methods for making transgenic mice
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
FI94339C
(fi)
|
1989-07-21 |
1995-08-25 |
Warner Lambert Co |
Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
|
|
US5859205A
(en)
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
|
US6075181A
(en)
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
|
US6150584A
(en)
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
DE69120146T2
(de)
|
1990-01-12 |
1996-12-12 |
Cell Genesys Inc |
Erzeugung xenogener antikörper
|
|
FR2664073A1
(fr)
|
1990-06-29 |
1992-01-03 |
Thomson Csf |
Moyens de marquage d'objets, procede de realisation et dispositif de lecture.
|
|
US5633425A
(en)
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
WO1993012227A1
(en)
|
1991-12-17 |
1993-06-24 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
ATE158021T1
(de)
|
1990-08-29 |
1997-09-15 |
Genpharm Int |
Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
|
|
US5770429A
(en)
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5874299A
(en)
|
1990-08-29 |
1999-02-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
|
DE69133557D1
(de)
|
1990-08-29 |
2007-03-15 |
Pharming Intellectual Pty Bv |
Homologe rekombination in säugetier-zellen
|
|
US5877397A
(en)
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5661016A
(en)
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
|
US5625126A
(en)
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5789650A
(en)
|
1990-08-29 |
1998-08-04 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
|
US5814318A
(en)
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
|
US6255458B1
(en)
|
1990-08-29 |
2001-07-03 |
Genpharm International |
High affinity human antibodies and human antibodies against digoxin
|
|
WO1992022670A1
(en)
|
1991-06-12 |
1992-12-23 |
Genpharm International, Inc. |
Early detection of transgenic embryos
|
|
WO1992022645A1
(en)
|
1991-06-14 |
1992-12-23 |
Genpharm International, Inc. |
Transgenic immunodeficient non-human animals
|
|
WO1994004679A1
(en)
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
|
JP2648897B2
(ja)
|
1991-07-01 |
1997-09-03 |
塩野義製薬株式会社 |
ピリミジン誘導体
|
|
WO1993004169A1
(en)
|
1991-08-20 |
1993-03-04 |
Genpharm International, Inc. |
Gene targeting in animal cells using isogenic dna constructs
|
|
US5565332A
(en)
|
1991-09-23 |
1996-10-15 |
Medical Research Council |
Production of chimeric antibodies - a combinatorial approach
|
|
PT1024191E
(pt)
|
1991-12-02 |
2008-12-22 |
Medical Res Council |
Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
|
|
US5869619A
(en)
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
|
EP0571613B1
(en)
|
1991-12-13 |
2003-09-17 |
Xoma Corporation |
Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
|
|
AU4541093A
(en)
|
1992-06-18 |
1994-01-24 |
Genpharm International, Inc. |
Methods for producing transgenic non-human animals harboring a yeast artificial chromosome
|
|
ES2301158T3
(es)
|
1992-07-24 |
2008-06-16 |
Amgen Fremont Inc. |
Produccion de anticuerpos xenogenicos.
|
|
US6066718A
(en)
|
1992-09-25 |
2000-05-23 |
Novartis Corporation |
Reshaped monoclonal antibodies against an immunoglobulin isotype
|
|
US5981175A
(en)
|
1993-01-07 |
1999-11-09 |
Genpharm Internation, Inc. |
Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
|
|
JPH08509612A
(ja)
|
1993-04-26 |
1996-10-15 |
ジェンファーム インターナショナル インコーポレイテッド |
異種抗体を産生することができるトランスジェニック非ヒト動物
|
|
US5625825A
(en)
|
1993-10-21 |
1997-04-29 |
Lsi Logic Corporation |
Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
|
|
US5643763A
(en)
|
1994-11-04 |
1997-07-01 |
Genpharm International, Inc. |
Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
|
|
WO1996034096A1
(en)
|
1995-04-28 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
|
US5977322A
(en)
|
1995-06-14 |
1999-11-02 |
The Regents Of The University Of California |
High affinity human antibodies to tumor antigens
|
|
US6127977A
(en)
|
1996-11-08 |
2000-10-03 |
Cohen; Nathan |
Microstrip patch antenna with fractal structure
|
|
KR100308764B1
(ko)
|
1995-08-29 |
2001-12-17 |
마나배게이사꾸 |
키메라동물및그의제작법
|
|
GB9610992D0
(en)
|
1996-05-24 |
1996-07-31 |
Glaxo Group Ltd |
Concentrated antibody preparation
|
|
WO1998001100A2
(en)
|
1996-07-09 |
1998-01-15 |
Merck & Co., Inc. |
Method for treating homozygous familial hypercholesterolemia
|
|
EP0852951A1
(de)
|
1996-11-19 |
1998-07-15 |
Roche Diagnostics GmbH |
Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
|
|
CA2722378C
(en)
|
1996-12-03 |
2015-02-03 |
Amgen Fremont Inc. |
Human antibodies that bind tnf.alpha.
|
|
US6133426A
(en)
|
1997-02-21 |
2000-10-17 |
Genentech, Inc. |
Humanized anti-IL-8 monoclonal antibodies
|
|
US7968689B2
(en)
|
1997-03-07 |
2011-06-28 |
Human Genome Sciences, Inc. |
Antibodies to HSDEK49 polypeptides
|
|
US20050197285A1
(en)
|
1997-03-07 |
2005-09-08 |
Rosen Craig A. |
Human secreted proteins
|
|
US20070224663A1
(en)
|
1997-03-07 |
2007-09-27 |
Human Genome Sciences, Inc. |
Human Secreted Proteins
|
|
US7368531B2
(en)
|
1997-03-07 |
2008-05-06 |
Human Genome Sciences, Inc. |
Human secreted proteins
|
|
US20080103090A1
(en)
|
1997-03-07 |
2008-05-01 |
Human Genome Sciences, Inc. |
Human Secreted Proteins
|
|
US20070055056A1
(en)
|
1997-03-07 |
2007-03-08 |
Rosen Craig A |
251 human secreted proteins
|
|
US20060223090A1
(en)
|
1997-03-07 |
2006-10-05 |
Rosen Craig A |
Polynucleotides encoding human secreted proteins
|
|
US20060246483A1
(en)
|
1997-03-07 |
2006-11-02 |
Rosen Craig A |
337 human secreted proteins
|
|
US20060223088A1
(en)
|
1997-03-07 |
2006-10-05 |
Rosen Craig A |
Human secreted proteins
|
|
US7411051B2
(en)
|
1997-03-07 |
2008-08-12 |
Human Genome Sciences, Inc. |
Antibodies to HDPPA04 polypeptide
|
|
US20070015696A1
(en)
|
1997-03-07 |
2007-01-18 |
Rosen Craig A |
621 human secreted proteins
|
|
US20070059302A1
(en)
|
1997-04-07 |
2007-03-15 |
Genentech, Inc. |
Anti-vegf antibodies
|
|
US6252050B1
(en)
|
1998-06-12 |
2001-06-26 |
Genentech, Inc. |
Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
|
|
US6660843B1
(en)
|
1998-10-23 |
2003-12-09 |
Amgen Inc. |
Modified peptides as therapeutic agents
|
|
US6833268B1
(en)
|
1999-06-10 |
2004-12-21 |
Abgenix, Inc. |
Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
|
|
EP1514933A1
(en)
|
1999-07-08 |
2005-03-16 |
Research Association for Biotechnology |
Secretory protein or membrane protein
|
|
US7605238B2
(en)
|
1999-08-24 |
2009-10-20 |
Medarex, Inc. |
Human CTLA-4 antibodies and their uses
|
|
US20030119038A1
(en)
|
1999-09-09 |
2003-06-26 |
Bingham Brendan William |
NARC1, novel subtilase-like homologs
|
|
US20100291099A1
(en)
|
1999-09-27 |
2010-11-18 |
Millennium Pharmaceuticals, Inc. |
Novel 27411, 23413, 22438, 23553, 25278, 26212, narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, narc 25, 86604 and 32222 molecules and uses therefor
|
|
US7029895B2
(en)
|
1999-09-27 |
2006-04-18 |
Millennium Pharmaceuticals, Inc. |
27411, a novel human PGP synthase
|
|
US20020081679A1
(en)
|
1999-10-22 |
2002-06-27 |
Millennium Pharmaceuticals, Inc. |
NARC8 programmed cell-death-associated molecules and uses thereof
|
|
EP1226243A2
(en)
|
1999-10-22 |
2002-07-31 |
Millennium Pharmaceuticals, Inc. |
Nucleic acid molecules derived from rat brain and programmed cell death models
|
|
US20110230392A1
(en)
|
1999-10-22 |
2011-09-22 |
Millennium Pharmaceuticals, Inc. |
Novel narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, and narc 25 molecules and uses therefor
|
|
EP1257572A2
(en)
|
2000-02-07 |
2002-11-20 |
Millennium Pharmaceuticals, Inc. |
Narc-1, subtilase-like homologs
|
|
AU5943201A
(en)
|
2000-05-03 |
2001-11-12 |
Amgen Inc |
Modified peptides as therapeutic agents
|
|
WO2001098468A2
(en)
|
2000-06-16 |
2001-12-27 |
Incyte Genomics, Inc. |
Proteases
|
|
WO2002014358A2
(en)
|
2000-08-11 |
2002-02-21 |
Eli Lilly And Company |
Novel secreted proteins and their uses
|
|
AU2002213441B2
(en)
|
2000-10-12 |
2006-10-26 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
|
AU2001295337A1
(en)
|
2000-10-20 |
2002-04-29 |
Ian Crandall |
E. histolytica-specific antibodies and clinical uses thereof
|
|
JP2005500005A
(ja)
|
2000-12-08 |
2005-01-06 |
インサイト・ゲノミックス・インコーポレイテッド |
タンパク質修飾分子とメンテナンス分子
|
|
EP1379264A4
(en)
|
2001-03-21 |
2009-07-08 |
Human Genome Sciences Inc |
HUMAN SECRETED PROTEINS
|
|
US20040023243A1
(en)
|
2001-06-13 |
2004-02-05 |
Yue Henry |
Proteases
|
|
CA2450793A1
(en)
|
2001-06-20 |
2002-12-27 |
Prochon Biotech Ltd. |
Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
|
|
US20040038242A1
(en)
|
2001-07-30 |
2004-02-26 |
Edmonds Brian Taylor |
Novel secreted proteins and their uses
|
|
US20040009178A1
(en)
|
2002-02-11 |
2004-01-15 |
Bowdish Katherine S. |
Immunotherapeutics for biodefense
|
|
WO2004017986A1
(en)
|
2002-08-23 |
2004-03-04 |
Valorisation-Recherche, Societe En Commandite |
Growth hormone-releasing peptides in the treatment of prevention of atherosclerosis and hypercholesterolemia
|
|
US6875433B2
(en)
|
2002-08-23 |
2005-04-05 |
The United States Of America As Represented By The Secretary Of The Army |
Monoclonal antibodies and complementarity-determining regions binding to Ebola glycoprotein
|
|
KR101317045B1
(ko)
|
2002-09-06 |
2013-10-16 |
암젠 인코포레이티드 |
치료학적 인체 항-ｉｌ-1ｒ1 모노클로날 항체
|
|
AR047392A1
(es)
|
2002-10-22 |
2006-01-18 |
Wyeth Corp |
Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines
|
|
AU2003293543A1
(en)
|
2002-12-13 |
2004-07-09 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
|
US20050158303A1
(en)
|
2003-04-04 |
2005-07-21 |
Genentech, Inc. |
Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
|
|
EP1471152A1
(en)
|
2003-04-25 |
2004-10-27 |
Institut National De La Sante Et De La Recherche Medicale (Inserm) |
Mutations in the human PCSK9 gene associated to hypercholesterolemia
|
|
EP1633785B1
(en)
|
2003-05-21 |
2012-11-28 |
Medarex, Inc. |
Human monoclonal antibodies against bacillusanthracis protective antigen
|
|
US20050118625A1
(en)
|
2003-10-02 |
2005-06-02 |
Mounts William M. |
Nucleic acid arrays for detecting gene expression associated with human osteoarthritis and human proteases
|
|
JP2005130764A
(ja)
|
2003-10-30 |
2005-05-26 |
Pharmaceuticals & Medical Devices Agency |
Ｎａｒｃ−１遺伝子上の多型を利用した脂質代謝異常に起因する疾患の検査方法、および創薬のための用途
|
|
CN1897918A
(zh)
|
2003-11-17 |
2007-01-17 |
阿尔萨公司 |
包含两亲性分子作为混悬载体的组合物和剂型
|
|
WO2005077407A1
(en)
|
2004-01-16 |
2005-08-25 |
Barnes-Jewish Hospital |
Targeted atherosclerosis treatment
|
|
ES2401114T3
(es)
|
2004-08-10 |
2013-04-17 |
Genzyme Corporation |
Modulación antisentido de la expresión de apolipoproteína B
|
|
US20060147945A1
(en)
|
2005-01-06 |
2006-07-06 |
Edmonds Brian T |
Novel secreted proteins and their uses
|
|
US7906625B2
(en)
|
2005-01-24 |
2011-03-15 |
Amgen Inc. |
Humanized anti-amyloid antibody
|
|
WO2006124269A2
(en)
|
2005-05-16 |
2006-11-23 |
Amgen Fremont Inc. |
Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders
|
|
BRPI0611901A2
(pt)
*
|
2005-06-14 |
2012-08-28 |
Amgen, Inc |
composição, liofilizado, kit, e, processo para preparar uma composição
|
|
US8304383B2
(en)
|
2005-11-22 |
2012-11-06 |
Atheronova Operations, Inc. |
Dissolution of arterial plaque
|
|
WO2007074880A1
(ja)
|
2005-12-28 |
2007-07-05 |
Chugai Seiyaku Kabushiki Kaisha |
抗体含有安定化製剤
|
|
WO2007089753A2
(en)
|
2006-01-26 |
2007-08-09 |
Hx Diagnostics, Inc. |
Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof
|
|
CA2652247C
(en)
|
2006-05-08 |
2015-11-17 |
Adaerata, Limited Partnership |
Chimeric pcsk9 proteins, cells comprising same, and assays using same
|
|
CN101484588B
(zh)
|
2006-05-11 |
2013-11-06 |
阿尔尼拉姆医药品有限公司 |
抑制pcsk9基因表达的组合物和方法
|
|
US7572618B2
(en)
|
2006-06-30 |
2009-08-11 |
Bristol-Myers Squibb Company |
Polynucleotides encoding novel PCSK9 variants
|
|
AU2007297388A1
(en)
|
2006-09-18 |
2008-03-27 |
Alnylam Pharmaceuticals, Inc. |
RNAi modulation of scap and therapeutic uses thereof
|
|
US20100068194A1
(en)
|
2006-10-24 |
2010-03-18 |
Dong-Ku Kim |
Composition for in vivo transplantation for treatment of human cervical cancer comprising mononuclear cells derived from umbilical cord blood
|
|
WO2008057458A2
(en)
|
2006-11-07 |
2008-05-15 |
Merck & Co., Inc. |
Antagonists of pcsk9
|
|
US20100040611A1
(en)
|
2006-11-07 |
2010-02-18 |
Sparrow Carl P |
Antagonists of pcsk9
|
|
WO2008057459A2
(en)
|
2006-11-07 |
2008-05-15 |
Merck & Co., Inc. |
Antagonists of pcsk9
|
|
US20100040610A1
(en)
|
2006-11-07 |
2010-02-18 |
Ayesha Sitlani |
Antagonists of pcsk9
|
|
FR2909092B1
(fr)
|
2006-11-24 |
2012-10-19 |
Pf Medicament |
Nouveaux anticorps anti-proliferation
|
|
CA2674608A1
(en)
|
2007-01-09 |
2008-07-17 |
Wyeth |
Anti-il-13 antibody formulations and uses thereof
|
|
WO2008109871A2
(en)
|
2007-03-08 |
2008-09-12 |
Irm Llc |
Crystal structure of proprotein convertase 9 (pcsk9) and uses thereof
|
|
CA2682292A1
(en)
|
2007-03-30 |
2008-10-09 |
Medimmune, Llc |
Aqueous formulation comprising an anti-human interferon alpha antibody
|
|
EA200901376A1
(ru)
|
2007-04-13 |
2010-12-30 |
Новартис Аг |
Молекулы и способы модуляции пропротеинконвертазы субтилизинового/кексинового типа 9(pcsk9)
|
|
CA2696164C
(en)
|
2007-08-13 |
2018-06-12 |
Vasgene Therapeutics, Inc. |
Cancer treatment using humanized antibodies that bind to ephb4
|
|
EP2615114B1
(en)
|
2007-08-23 |
2022-04-06 |
Amgen Inc. |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
|
|
US20130072665A1
(en)
|
2007-08-23 |
2013-03-21 |
Simon Mark Jackson |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
|
|
JOP20080381B1
(ar)
|
2007-08-23 |
2023-03-28 |
Amgen Inc |
بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
|
|
US8623650B2
(en)
|
2007-10-19 |
2014-01-07 |
Viacyte, Inc. |
Methods and compositions for feeder-free pluripotent stem cell media containing human serum
|
|
NZ584902A
(en)
|
2007-10-26 |
2012-03-30 |
Schering Corp |
Anti-pcsk9 and methods for treating lipid and cholesterol disorders
|
|
AR070316A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
|
|
AR070315A1
(es)
|
2008-02-07 |
2010-03-31 |
Merck & Co Inc |
Anticuerpos 1b20 antagonistas de pcsk9
|
|
EP2250199B1
(en)
|
2008-02-07 |
2015-09-02 |
Merck Sharp & Dohme Corp. |
Engineered anti-tslpr antibodies
|
|
KR102057826B1
(ko)
|
2008-04-11 |
2019-12-20 |
추가이 세이야쿠 가부시키가이샤 |
복수 분자의 항원에 반복 결합하는 항원 결합 분자
|
|
MX2010011499A
(es)
|
2008-04-23 |
2010-11-12 |
Amgen Inc |
Variantes de proproteina neutralizante de convertasa subtilisina kexina de tipo 9 (pcsk9) y sus usos.
|
|
US20090275053A1
(en)
|
2008-04-30 |
2009-11-05 |
Board Of Regents, The University Of Texas System |
Cell-based pcsk9 screening assay
|
|
CA2729961C
(en)
|
2008-07-09 |
2018-05-01 |
Biogen Idec Ma Inc. |
Li113, li62 variant co2, anti-lingo antibodies
|
|
EP2641918A3
(en)
|
2008-08-04 |
2014-03-05 |
Amgen Inc. |
Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (PCSK9)
|
|
TWI516501B
(zh)
|
2008-09-12 |
2016-01-11 |
禮納特神經系統科學公司 |
Ｐｃｓｋ９拮抗劑類
|
|
CA2738243C
(en)
|
2008-10-29 |
2020-09-29 |
Wyeth Llc |
Formulations of single domain antigen binding molecules
|
|
WO2010068526A1
(en)
|
2008-12-12 |
2010-06-17 |
Merck Sharp & Dohme Corp. |
Pcsk9 immunoassay
|
|
JO3672B1
(ar)
|
2008-12-15 |
2020-08-27 |
Regeneron Pharma |
أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
|
|
US20130064834A1
(en)
|
2008-12-15 |
2013-03-14 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to pcsk9
|
|
US8357371B2
(en)
|
2008-12-15 |
2013-01-22 |
Regeneron Pharmaceuticals, Inc. |
Methods for treating hypercholesterolemia using antibodies to PCSK9
|
|
CL2011001435A1
(es)
|
2008-12-15 |
2012-02-24 |
Regeneron Pharma |
Anticuerpo humano que se une especificamente a la proteina convertasa subtilisina/kexuba/kexina de tipo 9 humana (hpcsk9) o fragmento de union a antigeno del mismo; molecula de acido nucleico que lo codifica; vector de expresion; metodo de produccion; composicion farmaceutica; y su uso para tratar una enfermedad relacionada con hpcsk9.
|
|
WO2010078536A1
(en)
|
2009-01-05 |
2010-07-08 |
Rxi Pharmaceuticals Corporation |
Inhibition of pcsk9 through rnai
|
|
AU2010221156A1
(en)
|
2009-03-06 |
2011-09-22 |
Genentech, Inc. |
Antibody formulation
|
|
EP2456870A1
(en)
|
2009-07-21 |
2012-05-30 |
Santaris Pharma A/S |
Antisense oligomers targeting pcsk9
|
|
WO2011028938A1
(en)
|
2009-09-02 |
2011-03-10 |
Alnylam Pharmaceuticals, Inc. |
Methods for lowering serum cholestrol in a subject using inhibition of pcsk9
|
|
US20120219558A1
(en)
|
2009-09-25 |
2012-08-30 |
Yan Ni |
Antagonists of pcsk9
|
|
US20120208209A1
(en)
|
2009-10-30 |
2012-08-16 |
Marina Ichetovkin |
Pcsk9 immunoassay
|
|
CN102596249A
(zh)
|
2009-10-30 |
2012-07-18 |
默沙东公司 |
Ax1和ax189 pcsk9拮抗剂和变体
|
|
IN2012DN03824A
(pl)
|
2009-10-30 |
2015-08-28 |
Merck Sharp & Dohme |
|
|
WO2011053665A1
(en)
|
2009-10-30 |
2011-05-05 |
Merck Sharp & Dohme Corp. |
Pcsk9 immunoassay
|
|
EP2501408B1
(en)
|
2009-11-20 |
2020-05-27 |
Biocon Limited |
Formulations of antibody
|
|
AR079336A1
(es)
|
2009-12-11 |
2012-01-18 |
Irm Llc |
Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
|
|
PH12012501364A1
(en)
|
2010-01-15 |
2012-10-22 |
Amgen K A Inc |
Antibody formulation and therapeutic regimens
|
|
US20110207759A1
(en)
|
2010-02-19 |
2011-08-25 |
Taylor Allen John |
Method for treatment of atherosclerotic disease
|
|
WO2011109415A2
(en)
|
2010-03-02 |
2011-09-09 |
Amgen Inc. |
Reducing viscosity of pharmaceutical formulations
|
|
JP5932670B2
(ja)
|
2010-03-11 |
2016-06-08 |
ライナット ニューロサイエンス コーポレイション |
ｐＨ依存性の抗原結合を有する抗体
|
|
EP2558491B1
(en)
|
2010-04-13 |
2018-07-04 |
Bristol-Myers Squibb Company |
Fibronectin based scaffold domain proteins that bind pcsk9
|
|
CN201712554U
(zh)
|
2010-07-14 |
2011-01-19 |
李辉 |
电动汽车热管理系统
|
|
WO2012054438A1
(en)
|
2010-10-22 |
2012-04-26 |
Schering Corporation |
Anti-pcsk9
|
|
CN103261230A
(zh)
|
2010-12-22 |
2013-08-21 |
霍夫曼-拉罗奇有限公司 |
抗pcsk9抗体及使用方法
|
|
EP2650016A1
(en)
|
2011-01-28 |
2013-10-16 |
Sanofi |
Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565)
|
|
SG192117A1
(en)
|
2011-01-28 |
2013-08-30 |
Sanofi Sa |
Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
|
|
EP2481758A1
(en)
|
2011-01-28 |
2012-08-01 |
Sanofi |
Human antibodies to PSCK9 for use in methods of treating particular groups of subjects (11566)
|
|
WO2012109097A1
(en)
|
2011-02-10 |
2012-08-16 |
Trustees Of Dartmouth College |
Methods for increasing plasmin activity and promoting plaque regression in the treatment of atherosclerosis
|
|
WO2012109530A1
(en)
|
2011-02-11 |
2012-08-16 |
Irm Llc |
Pcsk9 antagonists
|
|
JOP20200043A1
(ar)
*
|
2011-05-10 |
2017-06-16 |
Amgen Inc |
طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
|
|
US20140004122A1
(en)
|
2011-05-10 |
2014-01-02 |
Amgen Inc. |
Methods for treating or preventing cholesterol related disorders
|
|
WO2012168491A1
(en)
|
2011-06-10 |
2012-12-13 |
Novartis Ag |
Pharmaceutical formulations of pcsk9 antagonists
|
|
WO2012170607A2
(en)
|
2011-06-10 |
2012-12-13 |
Novartis Ag |
Use of pcsk9 antagonists
|
|
WO2012177741A1
(en)
|
2011-06-20 |
2012-12-27 |
Genentech, Inc. |
Pcsk9-binding polypeptides and methods of use
|
|
BR112014000392A2
(pt)
|
2011-07-14 |
2017-02-21 |
Pfizer |
tratamento com anticorpos anti-pcsk9
|
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
|
AR087715A1
(es)
|
2011-09-16 |
2014-04-09 |
Lilly Co Eli |
Anticuerpos anti pcsk9 y usos de los mismos
|
|
HUE069234T2
(hu)
|
2011-09-16 |
2025-02-28 |
Regeneron Pharma |
Eljárások lipoprotein(a)-szint csökkentésére proprotein-konvertáz szubtilizin/kexin 9 (PCSK9) inhibitorának beadásával
|
|
US9879093B2
(en)
|
2011-12-20 |
2018-01-30 |
Adaerata, Limited Partnershp |
Single domain antibodies as inhibitors of PCSK9
|
|
WO2013148284A1
(en)
|
2012-03-29 |
2013-10-03 |
Genentech, Inc. |
Antibodies that bind to a pcsk9 cleavage site and methods of use
|
|
US9255154B2
(en)
|
2012-05-08 |
2016-02-09 |
Alderbio Holdings, Llc |
Anti-PCSK9 antibodies and use thereof
|
|
WO2013180295A1
(ja)
|
2012-06-01 |
2013-12-05 |
日本電信電話株式会社 |
パケット転送処理方法およびパケット転送処理装置
|
|
EP2861624A1
(en)
|
2012-06-15 |
2015-04-22 |
F. Hoffmann-La Roche AG |
Anti-pcsk9 antibodies, formulations, dosing, and methods of use
|
|
EP2703009A1
(en)
|
2012-08-31 |
2014-03-05 |
Sanofi |
Combination treatments involving antibodies to human PCSK9
|
|
EP2706070A1
(en)
|
2012-09-06 |
2014-03-12 |
Sanofi |
Combination treatments involving antibodies to human PCSK9
|
|
DK3199552T3
(da)
|
2012-11-20 |
2020-03-30 |
Sanofi Sa |
Anti-ceacam5-antistoffer og anvendelser heraf
|
|
WO2014150983A2
(en)
|
2013-03-15 |
2014-09-25 |
Amgen Inc. |
Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
|
|
JP6071725B2
(ja)
|
2013-04-23 |
2017-02-01 |
カルソニックカンセイ株式会社 |
電気自動車の駆動力制御装置
|
|
EP2862877A1
(en)
|
2013-10-18 |
2015-04-22 |
Sanofi |
Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9
|
|
US20150004174A1
(en)
|
2013-06-28 |
2015-01-01 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolemia
|
|
CA2916259C
(en)
|
2013-06-28 |
2024-02-20 |
Amgen Inc. |
Methods for treating homozygous familial hypercholesterolemia
|
|
US9300829B2
(en)
|
2014-04-04 |
2016-03-29 |
Canon Kabushiki Kaisha |
Image reading apparatus and correction method thereof
|
|
CA2954773C
(en)
|
2014-07-14 |
2023-10-03 |
Amgen Inc. |
Crystalline antibody formulations
|
|
KR20230074283A
(ko)
|
2014-07-16 |
2023-05-26 |
사노피 바이오테크놀로지 |
이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법
|
|
WO2016046684A1
(en)
|
2014-09-23 |
2016-03-31 |
Pfizer Inc. |
Treatment with anti-pcsk9 antibodies
|
|
HUE069048T2
(hu)
|
2015-01-09 |
2025-02-28 |
Global Genomics Group Llc |
Vér alapú biomarkerek ateroszklerotikus koszorúér-betegség diagnosztizálására
|
|
EA039310B1
(ru)
|
2015-02-26 |
2022-01-12 |
Санофи Байотекнолоджи |
Способы снижения сердечно-сосудистого риска
|
|
GB201510758D0
(en)
|
2015-06-18 |
2015-08-05 |
Ucb Biopharma Sprl |
Novel TNFa structure for use in therapy
|
|
JP2018523684A
(ja)
|
2015-08-18 |
2018-08-23 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
リポタンパク質アフェレーシスを受けている高脂血症の患者を治療するための抗ｐｃｓｋ９阻害抗体
|
|
JOP20190112A1
(ar)
|
2016-11-14 |
2019-05-14 |
Amgen Inc |
علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي
|
|
JP7377596B2
(ja)
|
2017-02-22 |
2023-11-10 |
アムジエン・インコーポレーテツド |
低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
|
|
US11284893B2
(en)
|
2019-04-02 |
2022-03-29 |
Covidien Lp |
Stapling device with articulating tool assembly
|
|
CA3179316A1
(en)
|
2020-05-29 |
2021-12-02 |
Andrew W. HAMER |
Pcsk9 inhibitors and methods of use thereof to treat cholesterol-related disorders
|